The number of people affected by breast cancer is expected to grow rapidly in the fore-seeable future. At the same time, precision medicine is becoming a significant part of the treatment regimen. As the use of liquid biopsies becomes more widespread, the need for tissue biopsies is expected to increase significantly to ensure and identify the cancer cell tissue precisely to provide the best possible treatment. NeoDynamics has clear competitive advantages over the standard of care in tissue biopsy. From our point of view, NeoDynamicsis well-positioned to become an essential part of the future of biopsy- and treatment of cancer.

Länk till analysen